Global Next-Generation Sequencing (NGS) Market research report by Emergen Research delivers a comprehensive analysis of the market outlook, regulatory framework, and macro- and micro-economic factors influencing the growth of the market. The report is formulated through extensive research and surveys to offer accurate and authentic information about the market size, market share, product portfolio, revenue generation, and projected market growth. The report offers key insights into the competitive and regional landscape of the market to assist the stakeholders and investors in formulating strategic business plans.

In today's competitive marketplace, staying ahead of the curve is essential for businesses of all sizes. Understanding consumer behavior, market trends, and emerging opportunities is crucial for making informed decisions and developing effective strategies. Emergen Research recognizes this need and has invested significant resources in developing a cutting-edge market research content library. 

The newly launched Next-Generation Sequencing (NGS) market research content is meticulously crafted by industry experts, leveraging extensive data analysis, and a deep understanding of various markets. This rich collection includes in-depth reports, whitepapers, case studies, trend analyses, and industry insights covering a wide range of sectors, including but not limited to technology, healthcare, finance, consumer goods, and manufacturing. 

Key points covered in the report:

• A detailed outlook of the market with essential data beneficial for business
• Market segmentation based on product types, applications, and end-users. For further understanding, the key segments are further divided into sub-segments
• Growth factors, driving and restraining factors, product trends, and technological advancements are extensively discussed
• Latest product developments, incorporation of new techniques and profiles of major competitors
• An 8-year forecast estimation detailing the growth and expansion scope of the Next-Generation Sequencing (NGS) market
• In-depth analysis of the forecast period (2024-2034)
• Market dynamics with information of players, challenges, restraints, threats, and opportunities
• SWOT analysis and Porter’s Five Forces analysis of the top vendors

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/8 

The global next-generation sequencing (NGS) market was valued at approximately USD 9.7 billion in 2024 and is projected to reach nearly USD 34.6 billion by 2034, registering a compound annual growth rate (CAGR) of around 13.6% during the forecast period.

The market represents a high-growth segment within the genomics and precision medicine ecosystem, driven by rapid advancements in sequencing technologies and expanding clinical applications. The transition from traditional sequencing methods to high-throughput NGS platforms has significantly improved speed, accuracy, and scalability, enabling large-scale genomic analysis across research and clinical settings.

In volume terms, the increasing burden of chronic and genetic diseases is supporting strong demand for sequencing technologies. According to global health estimates, cancer remains one of the leading causes of death worldwide, with millions of new cases diagnosed annually, driving the adoption of NGS in oncology research and diagnostics. Additionally, the use of sequencing in infectious disease surveillance and rare disease identification continues to expand, reinforcing demand across healthcare systems.

From an application perspective, NGS is increasingly being integrated into clinical diagnostics, drug discovery, and personalized medicine workflows. The growing adoption of precision medicine approaches is a key factor, as NGS enables identification of genetic mutations and supports targeted therapies. According to industry data, sequencing-based diagnostics and research applications are witnessing double-digit growth, supported by declining sequencing costs and increasing accessibility of genomic data.

From a strategic standpoint, the market is evolving into a technology-driven, high-investment domain, supported by strong funding in genomics research and national sequencing initiatives. Governments and research institutions are increasingly investing in large-scale genomics programs, further accelerating adoption.

Competitive Landscape: 

The latest study provides an insightful analysis of the broad competitive landscape of the global Next-Generation Sequencing (NGS) market, emphasizing the key market rivals and their company profiles. A wide array of strategic initiatives, such as new business deals, mergers & acquisitions, collaborations, joint ventures, technological upgradation, and recent product launches, undertaken by these companies has been discussed in the report. 

Increasing Adoption of Precision Medicine and Genomics-Based Therapies

The growing shift toward precision medicine is a major driver for the next-generation sequencing market. NGS enables identification of genetic mutations and biomarkers, supporting targeted therapies and personalized treatment strategies. According to the National Institutes of Health, large-scale initiatives such as the All of Us Research Program aim to collect genomic data from over 1 million participants, highlighting the scale of investment in precision medicine (NIH, 2024). This increasing integration of genomics into clinical decision-making is significantly driving demand for high-throughput sequencing technologies.

Rising Burden of Cancer and Genetic Disorders

The increasing incidence of cancer and genetic diseases is accelerating the adoption of NGS technologies in diagnostics and research. The World Health Organization estimates that cancer accounted for approximately 10 million deaths globally in 2022, making it one of the leading causes of mortality worldwide (WHO, 2023). NGS plays a critical role in oncology by enabling comprehensive genomic profiling, early detection, and monitoring of disease progression. Additionally, the growing focus on rare and inherited disorders is expanding the application scope of sequencing technologies, further supporting market growth.

Declining Cost of Sequencing and Technological Advancements

Continuous advancements in sequencing technologies have significantly reduced the cost of genome sequencing, making NGS more accessible across research and clinical settings. According to the National Human Genome Research Institute, the cost of sequencing a human genome has dropped from approximately USD 100 million in 2001 to below USD 1,000 in recent years (NHGRI, 2023). This dramatic cost reduction has enabled widespread adoption of NGS across laboratories, hospitals, and research institutions, while also supporting high-throughput sequencing and large-scale genomic studies.

Expanding Applications in Infectious Disease Surveillance and Drug Discovery

NGS is increasingly being used in infectious disease monitoring and drug development, further driving market demand. During global health crises such as COVID-19, sequencing technologies played a critical role in tracking virus mutations and variants. According to the Centers for Disease Control and Prevention, genomic surveillance programs have been essential in monitoring pathogen evolution and informing public health responses (CDC, 2023). In addition, pharmaceutical companies are leveraging NGS in drug discovery and clinical trials to identify novel targets and improve treatment outcomes, expanding its commercial applications.

Emergen Research is Offering a full report (Grab a Copy Now) @ https://www.emergenresearch.com/industry-report/next-generation-sequencing-market

The global next-generation sequencing (NGS) market was valued at approximately USD 9.7 billion in 2024 and is projected to reach nearly USD 34.6 billion by 2034, registering a compound annual growth rate (CAGR) of around 13.6% during the forecast period.

The market represents a high-growth segment within the genomics and precision medicine ecosystem, driven by rapid advancements in sequencing technologies and expanding clinical applications. The transition from traditional sequencing methods to high-throughput NGS platforms has significantly improved speed, accuracy, and scalability, enabling large-scale genomic analysis across research and clinical settings.

In volume terms, the increasing burden of chronic and genetic diseases is supporting strong demand for sequencing technologies. According to global health estimates, cancer remains one of the leading causes of death worldwide, with millions of new cases diagnosed annually, driving the adoption of NGS in oncology research and diagnostics. Additionally, the use of sequencing in infectious disease surveillance and rare disease identification continues to expand, reinforcing demand across healthcare systems.

From an application perspective, NGS is increasingly being integrated into clinical diagnostics, drug discovery, and personalized medicine workflows. The growing adoption of precision medicine approaches is a key factor, as NGS enables identification of genetic mutations and supports targeted therapies. According to industry data, sequencing-based diagnostics and research applications are witnessing double-digit growth, supported by declining sequencing costs and increasing accessibility of genomic data.

From a strategic standpoint, the market is evolving into a technology-driven, high-investment domain, supported by strong funding in genomics research and national sequencing initiatives. Governments and research institutions are increasingly investing in large-scale genomics programs, further accelerating adoption.

Market Segmentation: 

The report bifurcates the Next-Generation Sequencing (NGS) market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment. 

Key Companies Next Generation Sequencing Market

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Hoffmann-La Roche Ltd.
• BGI Genomics Co., Ltd.
• Agilent Technologies, Inc.
• QIAGEN N.V.
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies plc
• Revvity, Inc.
• Eurofins Scientific SE

The next-generation sequencing market is characterized by a highly competitive and moderately consolidated landscape, dominated by a mix of global life sciences companies and specialized sequencing technology providers. Leading players are focusing on technology innovation, platform scalability, and integrated genomics solutions to strengthen their market position.

Illumina, Inc. remains the dominant player in the NGS market, commanding a significant share through its industry-standard sequencing-by-synthesis platforms. The company’s ecosystem-driven model—combining instruments, consumables, and software—enables recurring revenue generation, with consumables contributing a majority share of its revenues.

Thermo Fisher Scientific Inc. and F. Hoffmann-La Roche Ltd. are key competitors leveraging their strong presence in diagnostics and life sciences. Thermo Fisher integrates sequencing platforms with its broader laboratory solutions portfolio, while Roche focuses on clinical diagnostics and oncology-driven sequencing applications. These companies benefit from extensive global distribution networks and strong penetration in clinical laboratories.

BGI Genomics represents a major player in the Asia Pacific region, offering cost-competitive sequencing platforms and large-scale genomic services. The company’s vertically integrated model and focus on high-throughput sequencing enable it to compete aggressively on pricing and volume, particularly in population-scale genomics projects.

Emerging technology-focused companies such as Pacific Biosciences (PacBio) and Oxford Nanopore Technologies are gaining traction in long-read sequencing and real-time genomic analysis. These technologies are increasingly being adopted for complex genomic applications, including structural variant detection and infectious disease surveillance, providing an alternative to traditional short-read sequencing platforms.

Companies such as Agilent Technologies, QIAGEN, and Revvity play a critical role in supporting the ecosystem through sample preparation, reagents, and bioinformatics solutions, while Eurofins Scientific strengthens the services segment through genomic testing and contract research capabilities.

Our goal at Emergen Research is to empower businesses with the knowledge and insights necessary to make informed decisions and thrive in today's dynamic business landscape. Our market research content is designed to equip professionals and organizations with comprehensive analyses, actionable recommendations, and a competitive edge to achieve their growth objectives. 

Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/8 

Target Audience of the Global Next-Generation Sequencing (NGS) Market Report: 

• Key Market Players 

• Investors 

• Venture capitalists 

• Small- and medium-sized and large enterprises 

• Third-party knowledge providers 

• Value-Added Resellers (VARs) 

• Global market producers, distributors, traders, and suppliers 

• Research organizations, consulting companies, and various alliances interested in this sector 

• Government bodies, independent regulatory authorities, and policymakers 

The global next-generation sequencing (NGS) market was valued at approximately USD 9.7 billion in 2024 and is projected to reach nearly USD 34.6 billion by 2034, registering a compound annual growth rate (CAGR) of around 13.6% during the forecast period.

The market represents a high-growth segment within the genomics and precision medicine ecosystem, driven by rapid advancements in sequencing technologies and expanding clinical applications. The transition from traditional sequencing methods to high-throughput NGS platforms has significantly improved speed, accuracy, and scalability, enabling large-scale genomic analysis across research and clinical settings.

In volume terms, the increasing burden of chronic and genetic diseases is supporting strong demand for sequencing technologies. According to global health estimates, cancer remains one of the leading causes of death worldwide, with millions of new cases diagnosed annually, driving the adoption of NGS in oncology research and diagnostics. Additionally, the use of sequencing in infectious disease surveillance and rare disease identification continues to expand, reinforcing demand across healthcare systems.

From an application perspective, NGS is increasingly being integrated into clinical diagnostics, drug discovery, and personalized medicine workflows. The growing adoption of precision medicine approaches is a key factor, as NGS enables identification of genetic mutations and supports targeted therapies. According to industry data, sequencing-based diagnostics and research applications are witnessing double-digit growth, supported by declining sequencing costs and increasing accessibility of genomic data.

From a strategic standpoint, the market is evolving into a technology-driven, high-investment domain, supported by strong funding in genomics research and national sequencing initiatives. Governments and research institutions are increasingly investing in large-scale genomics programs, further accelerating adoption.

About Emergen Research  

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. 

Contact Us: 

Eric Lee 

Corporate Sales Specialist 

Emergen Research | Web: https://www.emergenresearch.com/ 

Direct Line: +1 (604) 757-9756 

E-mail: sales@emergenresearch.com